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shown that people while still growing are more vulnerable
to the deleterious effects of smoking. Indeed, adolescents
are clearly the group most at risk for beginning to smoke.
The Pubilla-Casas Artery Study is a population-based
study designed to estimate prevalence, risk factors, and
prognosis of noninvasively assessed PAOD in elderly men.
The aim of this analysis was to define the risk of sympto-
matic PAOD associated with the age of smoking onset in
current or former male smokers.
METHODS
Study population. The target population comprised
all 55- to 74-year-old men of Pubilla Casas, an urban
neighborhood of Barcelona, Spain. At the time of the
study, Pubilla Casas had 29,000 inhabitants, of whom
3500 were men in this age category. Subjects with severe
mental disorders or terminal illnesses were excluded. At the
time of recruitment (1996), 85% of the censed population
was registered in the Pubilla Casas Primary Care Center,
attended by 14 general practitioners. All male subjects aged
55 to 74 years attended by 4 of these general practitioners
was recruited. To ensure representativity, a random sample
of 4/14 from the remaining 15% of the censed male pop-
ulation of the same age was added. This 2-stage sampling
method yielded 900 eligible men for the study. Of the 708
(78.7%) who agreed to participate, 573 (80.9%) were or
had been cigarette smokers and constituted the study sub-
jects. This sample size provided us with a statistical power
of 90% to detect a statistically significant result (P < .01) in
a 2-sided test showing a difference of 10% in the prevalence
of PAOD between early- and late-onset smoking age.
Informed consent was obtained from all participants to
define risk factor profile associated with PAOD. Both
physicians and participants were blinded to the purpose of
this study because some specific analyses of the Pubilla
Overwhelming and consistent evidence supports the
causal role of cigarette smoking in cardiovascular disease
(CVD).1 A large number of studies have analyzed the effect
on CVD of active and environmental exposure to tobacco
smoke and the benefits of smoking cessation.1-6 Con-
trasting with these data is the sparse information on the
potential impact of the age at smoking onset on CVD
development. Smoking onset at an early age could increase
the risk more than expected simply because exposure is
longer. To our knowledge, this issue for the risk of CVD has
received very little attention. The need to determine
whether an early starting age increases the risk of peripheral
arterial occlusive disease (PAOD) is supported by the fact
that smoking is the strongest risk factor known for the
development and progression of PAOD (about 3 of 4
affected patients are cigarette smokers),7 and early smoking
initiation has been suggested as a risk factor for certain
tobacco-related diseases, after adjusting for the degree of
exposure.8-10 Cardiovascular health promotion strategies in
childhood and adolescence would be reinforced if it were
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Purpose: The potential effects of age at onset of smoking on cardiovascular diseases have been studied little, in contrast to
the well-established evidence supporting a causal role of cigarette smoking in these diseases. We sought to analyze the rela-
tionship between age at smoking onset and development of symptomatic peripheral arterial occlusive disease (PAOD).
Methods: A population-based sample of 573 active or former male smokers aged 55 to 74 years were studied. Present
or previous symptomatic PAOD was confirmed by noninvasive testing.
Results: Sixty-one subjects (10.6%) had symptomatic PAOD. Prevalence of disease increased with earlier starting age
(15.6% if ≤16 years versus 5.4% if >16 years) of smoking. After controlling for risk factors that meet confounding fac-
tor criteria (ie, subject age and number of pack-years), men who started smoking at age 16 or earlier had a substan-
tially higher risk for development of PAOD (odds ratio, 2.19; 95% CI, 1.15-4.15; P = .016) than men who began to
smoke at a later age.
Conclusions: A starting age for smoking of 16 years or earlier more than doubles the risk of future symptomatic PAOD
regardless of the amount of exposure to cigarette smoking. (J Vasc Surg 2002;35:506-9)
Casas Artery Study (including the present objective) were
not outlined at the time of data collection.
Cardiovascular risk factors. Cardiovascular risk fac-
tors were assessed by personal physician interview at the
primary care center. Age was recorded in years at inclusion
in the study. Exposure to cigarette smoking was assessed
by a standard tobacco exposure questionnaire that allowed
for current or previous habit, pack-years, and age at which
smoking was begun. Previous smoker status was only
assigned when time since quitting to inclusion in the study
was at least 1 year. Pack-years were calculated as years of
smoking multiplied by the mean of 20-cigarette packs
consumed daily. Patients with PAOD were considered cur-
rent or ex-smokers according to their smoking status at
onset of symptoms (defined in the next section). Pack-
years in current smokers with PAOD included only expo-
sure until onset of symptoms. Age at onset of smoking was
categorized into 4 groups (<15 years, 15 to 16 years, 17
to 19 years, and >19 years) according to the sample size.
This categorization was set because no established cut-off
ages at onset of smoking for cardiovascular disease risk
assessment had been previously recommended. Hyper-
tension was defined by Fifth Joint National Committee
criteria11 or when the subject was receiving hypotensive
medication. Diabetes was defined by the criteria of the
World Health Organization12 or when the subject was
under treatment. Plasma cholesterol and triglyceride levels
were analyzed by standard methods in all subjects.
Subjects receiving medical treatment for dyslipidemia,
except those treated for secondary prevention, stopped
their medication for 6 weeks before cholesterol and
trygliceride levels were determined.
Peripheral arterial occlusive disease. PAOD was
defined as the presence of present or previous ischemic
symptoms in lower limbs (ie, intermittent claudication,
rest pain, or ischemic ulcers) and an abnormal ankle/
brachial index (ABI). Physicians at the primary health cen-
ter questioned all subjects about present or previous symp-
toms of intermittent claudication according to the
Edinburgh questionnaire,13 episodes suggestive of critical
leg ischemia (rest pain or ischemic ulcers), or revascular-
ization procedures, and they performed resting ABI mea-
surement with a calibrated mercury sphygmomanometer
and a handheld Doppler scanning device on all subjects.
Systolic pressure readings were obtained from both
humeral and posterior tibial and dorsalis pedis arteries of
both lower limbs after 5 minutes of bed rest. ABIs were
calculated by dividing feet readings by the mean of both
humeral pressures or by the highest if interarm asymmetry
(ie, >15 mm Hg) was observed. Four ABIs were therefore
obtained for each subject. 
All subjects who declared symptoms suggestive of
PAOD or those who presented any ABI less than 0.9 were
referred to a vascular surgery department for confirmation
and further evaluation. History was then taken by a vascu-
lar surgeon, and ABI was measured with the patient at rest
by an experienced vascular technician with a calibrated
sphygmomanometer and a bidirectional Doppler scanning
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device. Definite diagnosis of symptomatic PAOD was
made when both symptoms and at least 1 abnormal ABI
<0.9 were present.
Five symptom-free subjects had abnormally high
(>1.5) ABI readings of 1 limb; these were not excluded
from this analysis because none had PAOD symptoms.
Although stress testing was foreseen in the protocol, no
subject with a history of symptomatic PAOD who did not
undergo surgery had rest ABIs within the normal range.
Finally, a random sample of 80 normal-range ABIs
obtained by physicians at the primary health center was
verified by the vascular laboratory. None of these subjects
was found to have any abnormal ABI at vascular laboratory.
Statistical analysis. Differences between groups (sub-
jects with and without PAOD, late or early smoking-onset
age of subjects) were assessed by χ2 testing in categorical
variables and by Student t test or Mann-Whitney U test as
appropriate for continuous variables. The odds ratio and
95% confidence interval of PAOD associated with an early
smoking-onset age were calculated by use of unconditional
logistic regression. To control for potential confounding
factors, all variables related to both PAOD and smoking-
onset age, both with P < .15, were included in the model.
RESULTS
Sixty-one (10.6%) of the 573 adult-to-old men who
were previous or current cigarette smokers had ischemic
symptoms in lower limbs and an abnormal ABI. Subjects
with symptomatic PAOD declared earlier smoking-onset
ages than those declared by subjects without PAOD (P <
.001) (Table I). Symptomatic PAOD prevalence was simi-
lar within the first two groups of smoking-onset age
(16.6% and 14.4%, respectively) and also within the last
two groups (4.3% and 6.4%, respectively). Consequently, in
further analysis, subjects were divided into two smoking
categories according to their age at onset of smoking, hav-
ing as a cutoff the median value (ie, 16 years). PAOD
prevalence among subjects who started smoking at age 16
or earlier was 15.6% compared with 5.4% observed in those
who started later (P < .001). Five cases (8.2%) of the 61
patients with symptomatic PAOD had a history of devel-
opment of critical leg ischemia; all of them started smoking
at age 16 or earlier. Mean ABI of patients with symptoms
who started smoking at 16 or earlier was lower than that
observed in patients with symptoms who started later
(0.60 vs 0.64), although it was not statistically significant.
Table I. Prevalence of smoking-onset age groups in 
subjects with and without symptomatic PAOD
PAOD present PAOD absent
(n = 61) (n = 512)
≤14 y 28 (45.9%) 141 (27.5%)
15-16 y 18 (29.5%) 107 (20.9%)
17-19 y 6 (9.8%) 133 (26.0%)
>19 y 9 (14.8%) 131 (25.6%)
P < .001.
PAOD was associated with increased age (P = .003),
active smoking (P < .001), number of pack-years (P <
.001), diabetes (P < .001), hypertension (P = .009), and
increased triglyceride levels (P = .02) (Table II). Age at
onset of smoking was associated with the number of pack-
years (P < .001) (Table III). In the multiple logistic
regression model adjusted for all confounding variables
(ie, age and pack-years), a smoking-onset age ≤16 years
was independently associated with symptomatic PAOD
(odds ratio, 2.19; 95% CI, 1.15-4.15; P = .016). Variables
included in the model did not correlate with one another
(no significant colinearity).
DISCUSSION
Tobacco smoking has been identified by the World
Health Organization as the most important preventable
cause of disease and premature death.14 In the cardiovas-
cular system smoking is responsible for as many as 30% of
all coronary artery diseases,15,16 doubles the risk of
ischemic stroke,17 and is the strongest risk factor known
for PAOD, with relative risk ratios up to 7.5.1,18,19 Many
investigators have analyzed the effects of active and envi-
ronmental exposure to cigarette smoking and the protec-
tive action of smoking cessation on CVD.1-6 In contrast
with this exhaustive information is the sparse information
available on the potential impact of age at onset of smok-
ing on CVD development. It may seem that the effects of
the duration of smoking are so strong and so closely
related to subject age and to smoking-onset age that it is
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virtually impossible to determine whether the latter has
any independent effect on CVD rates. In our study, how-
ever, a smoking-onset age of 16 years or earlier was clearly
associated with PAOD, and this effect remained significant
after adjusting for number of pack-years and subject age.
Increased endothelium vulnerability during childhood
or adolescence may account for a higher CVD risk among
smokers who had begun smoking at an early age. To our
knowledge, this issue has not been studied to date, and no
experimental background can be offered to explain our epi-
demiologic findings. However, some data support the the-
ory that during maturation the endothelium may be more
susceptible to the deleterious effects of tobacco compounds:
(1) atherosclerosis is a lifelong disease that begins in child-
hood,20,21 with cholesterol concentrations and smoking
being important determinants of the early stages of the dis-
ease22; (2) an early smoking-onset age has also been
reported, although not precisely explained, as a risk factor
for ischemic stroke in women who had previously smoked8;
and (3) smoking onset during maturation has been sug-
gested to increase the risk for some neoplastic diseases.9,10
Recognition of an early smoking-onset age as an inde-
pendent risk factor for CVD may have a positive effect on
cardiovascular health promotion in children and adoles-
cents, because23 (1) adolescents are the group at maximum
risk for beginning to smoke; (2) adolescents recognize the
health consequences of smoking but see them as remote
and dose-dependent (“There is time enough to quit”); and
(3) interventions directed toward preventing use, delaying
Table II. Characteristics of subjects according to the presence or absence of symptomatic PAOD
PAOD (n = 61) Non-PAOD (n = 512) P value
Age (y)* 66.9 ± 4.8 64.8 ± 5.2 .003
Present smokers† 52 (85.2%) 194 (37.9%) <.001
Pack-years* 53.9 ± 28.1 33.3 ± 23.3 <.001
Diabetes† 25 (40.9%) 94 (18.4%) <.001
Hypertension† 44 (72.1%) 280 (54.8%) .009
Cholesterol (mg/dL)* 228.8 ± 43.8 223.8 ± 40.2 NS
Triglycerides (mg/dL)* 155.4 ± 111.8 130.4 ± 73.2 .02
*Mean ± SD.
†Number of subjects (%).
NS, Not statistically significant.
Table III. Characteristics of subjects according to their smoking-onset age
Smoking-onset Smoking-onset
age ≤16 years (n = 294) age > 16 years (n = 279) P value
Age (y)* 65.4 ± 5.2 64.7 ± 5.2 .086
Present smokers† 131 (44.6%) 115 (41.2%) NS
Pack-years* 42.3 ± 26.8 28.4 ± 19.9 <.001
Diabetes† 57 (19.4%) 62 (22.3%) NS
Hypertension† 172 (58.5%) 152 (54.7%) NS
Cholesterol (mg/dL)* 222.2 ± 40 226.7 ± 41.2 NS
Triglycerides (mg/dL)* 132.6 ± 75.2 133.5 ± 81.9 NS
*Mean ± SD.
†Number of subjects (%).
NS, Not statistically significant.
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onset, or minimizing smoking among adolescents are likely
to prevent habitual use. This additional risk associated with
an early smoking-onset age may help health promoters pre-
vent or delay smoking initiation in teenagers. This new and
powerful tool would be clearly reinforced if this association
were also reported for coronary artery disease.
This study focused on PAOD because of its close rela-
tionship with cigarette smoking. It seemed logical that if
smoking-onset age had any role in CVD development, it
would appear first and clearly in this CVD form for which
smoking is almost a necessary condition. PAOD was stud-
ied by anamnesis and noninvasive testing in all of the pop-
ulation studied. PAOD anamnesis was recorded because it
allowed us to define a date of (symptomatic) development
of PAOD and thus calculate cigarette exposure up to that
time. For this reason symptom-free subjects with an
abnormal ABI were not included as cases. We used a
screening algorithm that yielded very few false-positive or
false-negative results, if any. Diagnosis was verified in all
subjects with suspicious symptoms or abnormal ABI by a
qualified vascular surgeon. Similarly, a sample of symptom-
free subjects with normal ABI was also reassessed by the
same surgeon, and no false-negative results were found.
Subjects of the study constitute a surviving cohort, which
may have led to underestimation of the effect of smoking-
onset age because tobacco-related deaths are more fre-
quent among heavy smokers, many of whom might have
started smoking at an early age. No objective test was used
to provide evidence that a subject was not smoking.
Therefore it is possible that some subjects might have lied
about their smoking history. Conversely to the ability of
subjects to remember age at onset of smoking, some lack
of precision was observed about patient’s memory of
exactly when PAOD symptoms started. However, this
weakness of the study could be partially overcome because
(1) vascular history in all subjects with suspected PAOD
was performed by a vascular surgeon, and (2) symptoms in
most patients started earlier than 5 years of data collection.
In conclusion, our results suggest that a smoking-
onset age of 16 years or earlier is associated with more
than twice the risk of PAOD, independently of the num-
ber of cigarettes smoked. This finding may help to drive
home the message to our most skeptical audience—ado-
lescents—that cigarettes should be avoided.
We acknowledge the valuable contributions of Rosa
Faro for her task in the vascular laboratory, Marco Pavesi
for assistance in statistical analysis, and Christine O’Hara
for English revision of the manuscript.
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